Aardvark Therapeutics, Inc. (AARD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0029421007
Price
1.26 USD
Market cap
27.58 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Aardvark Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -62.73 m USD |
| EBIT | -62.73 m USD |
| Net income | -57.59 m USD |
| Diluted EPS – continuing operations | -2.93 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
More stocks
- QS Energy, Inc. (QSEP)
- Pelthos Therapeutics Inc. (PTHS)
- ISTE Co., Ltd. (212710.KQ)
- iANTHUS CAPITAL HOLDINGS, INC. (ITHUF)
- InspireMD, Inc. (NSPR)
- Xos, Inc. (XOS)
- ABUNDIA GLOBAL IMPACT GROUP, INC. (AGIG)
- Grandstand Limited (GRSD)
- WeShop Holdings Limited Class A Ordinary Shares (WSHP)
- SB Technology Holdings, Inc. (BIOM)
- Ankam, Inc. (ANKM)
- Genvor Inc (GNVR)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.